



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** September 2, 2011

**To:** Primary Clinical Research Associates

**From:** Tamra Losinski, MBA  
Research Protocol Specialist

**Re:** N0871, A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients with Measurable Disease with Cancer of Unknown Primary (CUP)

**This memo is regarding the shortage of paclitaxel.**

If you have paclitaxel available to use, you must use it, per protocol. However, if you do not have any available, you may omit paclitaxel and continue the other therapies. This must be documented on the Evaluation/Treatment Form. If supplies of paclitaxel to your site are an issue, it is advisable to avoid enrolling patients on the study and prioritizing paclitaxel for enrolled patients until the supply problem is resolved.

If you have any questions, please feel free to contact me.

Regards, Tamra